

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,

Petitioner,

v.

NOVO NORDISK A/S,

Patent Owner.

Case No. IPR2023-00723

Patent No. 8,129,343

**DECLARATION OF PETER FLATT, PH.D., IN SUPPORT OF PETITION
FOR *INTER PARTES* REVIEW OF
U.S. PATENT NO. 8,129,343**

TABLE OF CONTENTS

	Page
I. Introduction	10
II. Qualifications and Background.....	10
A. Education and Experience; Prior Testimony	10
B. Legal Standards and Materials Reviewed.....	14
C. Scope of Work	17
III. Person of Ordinary Skill in the Art.....	17
IV. The '343 Patent	20
V. Claim Construction	23
VI. Summary of Opinions	23
VII. Background on Diabetes, the Treatment of Diabetes, and GLP-1 Analogues.....	26
A. Diabetes	26
B. The Treatment of Diabetes.....	27
1. Insulin.....	27
2. Biguanides.....	28
3. Sulfonylureas	29
4. Thiazolidinediones.....	29
5. α -Glucosidase Inhibitors and Meglitinides.....	30
6. DPP-4 and PDE3 Inhibitors.....	30
7. The Rise of GLP-1 Based Drugs.....	31
C. Peptides and GLP-1 Analogues.....	35
1. General Peptide Chemistry.....	35
2. GLP-1 Peptides	38
3. Designing GLP-1 Analogues.....	42
4. Liraglutide.....	52
5. Semaglutide.....	54

TABLE OF CONTENTS
(continued)

	Page
VIII. The Challenged Claims of the '343 Patent Are Unpatentable As Obvious Under 35 U.S.C. § 103.....	57
A. Scope and Content of the Prior Art.....	57
1. Bridon (Ex. 1014).....	58
2. Dong (Ex. 1013).....	59
3. Knudsen 2001 (Ex. 1011)	61
4. Knudsen 2004 (Ex. 1010)	63
5. Knudsen Patent (Ex. 1012).....	66
6. Additional Prior Art References and Knowledge.....	69
B. Ground 1: The Challenged Claims of the '343 Patent Would Have Been Obvious Over Knudsen 2004 in View of the Knudsen Patent, Dong, and Bridon.....	78
1. Claims 1 and 4 of the '343 Patent.....	79
2. Claims 2 and 5 of the '343 Patent.....	120
3. Claims 3 and 6 of the '343 Patent.....	121
C. Ground 2: The Challenged Claims of the '343 Patent Would Have Been Obvious Over Knudsen 2001 in View of the Knudsen Patent, Dong, and Bridon.....	122
1. Claims 1 and 4 of the '343 Patent.....	122
2. Claims 2 and 5 of the '343 Patent.....	136
3. Claims 3 and 6 of the '343 Patent.....	137
D. Ground 3: The Challenged Claims of the '343 Patent Would Have Been Obvious in View of Common Drug Development Principles.....	138
IX. No Secondary Considerations Overcome <i>Prima Facie</i> Obviousness of the Claimed Subject Matter.....	142
A. Semaglutide Did Not Produce Any Unexpected or Surprising Results	143

TABLE OF CONTENTS
(continued)

	Page
B. The Prior Art Did Not Teach Away From Semaglutide.....	146
C. There Was No Long-Felt But Unmet Need.....	146
D. There Was No Industry Skepticism	147
E. Copying by Generic Drug Makers Is Irrelevant.....	147
X. CONCLUSION.....	148

TABLE OF ABBREVIATIONS

Full Name of Cited Reference	Abbreviation
U.S. Patent No. 8,129,343	'343 patent
U.S. Patent No. 5,512,549	'549 patent
Adelhorst, <i>Structure-Activity Studies of Glucagon-like Peptide-1*</i> , 269(9) J. BIO. CHEM. 6275 (1994)	Adelhorst
Banting, <i>The internal secretion of the pancreas</i> , 7 J LAB CLIN MED. 251 (1922)	Banting
Bayliss, <i>The Mechanism of Pancreatic Secretion</i> , 28(5) J. PHYSIOLOGY 325 (1902)	Bayliss
Bell, <i>Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides</i> , 302 NATURE 716 (1983)	Bell
U.S. Patent No. 6,514,500	Bridon
WO 91/11457	Buckley
Buse, <i>Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients with Type 2 Diabetes</i> , 27 DIABETES CARE 2628 (2004)	Buse
Chang, <i>The GLP-1 Derivative NN2211 Restores β-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose</i> , 52 DIABETES 1786 (2003)	Chang
Cistola, <i>Carbon 13 NMR Studies of Saturated Fatty Acids Bound to Bovine Serum Albumin I. The Filling of Individual Fatty Acid Binding Sites</i> , 262(23) J. BIO. CHEM. 10971 (1987)	Cistola I
Cistola, <i>Carbon 13 NMR Studies of Saturated Fatty Acids Bound to Bovine Serum Albumin II. Electrostatic Interactions in Individual Fatty Acid Binding Sites</i> , 262(23) J. BIO. CHEM. 10980 (1987)	Cistola II
Cooper, <i>Peptides as a Platform for Targeted Therapeutics for Cancer: Peptide – Drug Conjugates (PDCs)</i> , 50 CHEM. SOC. REV. 1480 (2021)	Cooper

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.